Trial · NCT07502521
Dexrazoxane to Protect Against Hemorrhagic STEMI
NCT07502521, Phase 2, Completed, Rohan Dharmakumar
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dexrazoxane to Protect Against Hemorrhagic STEMI. Trials, record NCT07502521. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07502521
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dexrazoxane to Protect Against Hemorrhagic STEMI
- NCT number
- NCT07502521
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Rohan Dharmakumar
- Conditions
- Acute Myocardial Infarction (AMI)
- Interventions
- Dexrazoxane, Normal Saline
- First posted
- 2026-03-31
- Last updated
- 2026-05-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Left Ventricular Ejection Fraction (LVEF) | 48-72 hours post-primary PCI | Global left ventricular systolic function expressed as a percentage, quantified by steady-state free-precession cine CMR |
| Primary | Intramyocardial Haemorrhage Burden (IMH %LV) | 48-72 hours post-primary PCI | Volume of intramyocardial haemorrhage expressed as a percentage of total left ventricular myocardial mass, quantified by multi-echo T2\*-weighted gradient-echo CMR |
| Secondary | Myocardial Infarct Size (Infarct %LV) | 48-72 hours post-primary PCI | Infarct size expressed as a percentage of total left ventricular myocardial mass, quantified by phase-sensitive inversion-recovery late gadolinium enhancement CMR. |
| Secondary | Microvascular Obstruction (MVO %LV) | 48-72 hours post-primary PCI | MVO expressed as a percentage of total left ventricular myocardial mass, identified as a hypointense core region within the LGE-defined infarct zone on late gadolinium enhancement CMR. |
| Other | Right Ventricular Ejection Fraction (RVEF) | 48-72 hours post-primary PCI | Global right ventricular systolic function expressed as a percentage, derived from contiguous short-axis SSFP cine CMR. |
| Other | High-Sensitivity Cardiac Troponin-I (hs-cTnI) | -1 hour pre-PCI through 48 hours post-primary PCI | Serial hs-cTnI concentrations (ng/L) measured at pre-specified timepoints: -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 16, 20, 24, and 48 hours relative to primary PCI. |
| Other | Incidence of Major Bleeding (BARC Criteria) | First dose through 30 days | Bleeding complications assessed using Bleeding Academic Research Consortium (BARC) criteria types 1-5. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07502521
GET https://conductscience.org/api/trials/v1/NCT07502521/registered